Cramer Explains Why He Likes Agios Pharmaceuticals (AGIO)

Cramer says Agios Pharmaceuticals is unique and different and yesterday its experimental cancer drug delivered some strong results in patients with advanced leukemia. The pharmaceutical company has developed a novel way to kill targeted cancer by attacking the 'metabolism' of cancer. Cramer predicts that if this $3 billion company continues to do as well as it has been, it will be bought by Celgene. As an investor, he says you win either way because Agios is still not expensive if this drug works and it looks like it's working. Shares of Agios were higher Wednesday following the positive preliminary data on its cancer drug.